Aadi Bioscience shares are trading lower after the company reported interim results from the PRECISION1 trial of nab-sirolimus.
Portfolio Pulse from Benzinga Newsdesk
Aadi Bioscience's stock price has declined following the release of interim results from the PRECISION1 trial of their drug nab-sirolimus.

December 15, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aadi Bioscience's shares have fallen after announcing interim results from the PRECISION1 trial of nab-sirolimus, indicating investor concern or disappointment with the trial outcomes.
The decline in Aadi Bioscience's stock price is likely due to the market's reaction to the interim trial results, which may not have met investor expectations or raised concerns about the drug's efficacy or commercial potential.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100